The Annual General Meeting of
The meeting also resolved to authorise the Board of directors to resolve on the repurchase of all issued class C shares by an offer directed to all holders of class C shares. Repurchase under this authorisation may be made on one or several occasions until the Annual General Meeting 2022 and at a price to no less than 100 per cent and no more than 105 per cent of the quotient value of the share.
The Board of directors has resolved to exercise the repurchase authorisation for the said purpose by repurchasing of all issued class C shares against payment of 100 per cent of the quotient value of the share, corresponding to approximately
The company currently holds 8,670,882 own common shares and no own class C shares. Subsequently to the effected repurchase of class C shares above, all repurchased class C shares are intended to be converted to common shares, where after the number of own common shares will amount to 11,969,866.
About Sobi(TM)
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Sobi is providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Sobi employs approximately 1,500 people across
For more information, please contact
Paula Treutiger, Head of Communication & Investor Relations
+46 733 666 599
paula.treutiger@sobi.com
+46 767 248 830
maria.kruse@sobi.com
The information was released for public distribution on
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/the-board-of-directors-exercises-authorisation-for-repurchase-of-shares-for-the-purpose-of-securing-,c3387663
https://mb.cision.com/Main/14266/3387663/1446948.pdf
(c) 2021 Cision. All rights reserved., source